^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GSK5733584

    i
    Other names: GSK5733584, HS-20089, GSK 5733584, HS 20089, GSK-5733584, HS20089
    Associations

    News

    Trials
    Company:
    GSK, Jiangsu Hansoh Pharma
    Drug class:
    Topoisomerase I inhibitor, B7-H4-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    2ms
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=240, Recruiting, GlaxoSmithKline | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    GSK5733584
    4ms
    HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=1048, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • Ariely (adebrelimab) • GSK5733584
    6ms
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=240, Not yet recruiting, GlaxoSmithKline
    New P1 trial • Metastases
    |
    GSK5733584
    8ms
    A Study of HS-20089 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=177, Recruiting, Shanghai Hansoh Biomedical Co., Ltd | Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    GSK5733584
    8ms
    HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer (clinicaltrials.gov)
    P2, N=460, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    GSK5733584
    8ms
    HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=1048, Not yet recruiting, Hansoh BioMedical R&D Company
    New P1 trial • Metastases
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • Ariely (adebrelimab) • GSK5733584
    over1year
    First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors (ESMO 2023)
    The patient achieving PR with the longest treatment duration of 403 days remains on treatment in 0.7 mg/kg cohort. Conclusions Based on data from the ongoing study, HS-20089 was well tolerated and showed antitumor activities in advanced solid tumors, with encouraging clinical efficacy in TNBC.
    Clinical • P1 data • Metastases
    |
    VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
    |
    GSK5733584